(CLS) Celestica - NYSE
Sector: Technology | Industry: Electronic Components | Exchange: NYSE (USA) | Market Cap: 45.198m USD | Total Return: 175.5% in 12m
Avg Turnover: 800M
EPS Trend: 99.0%
Qual. Beats: 0
Rev. Trend: 98.0%
Qual. Beats: 0
Warnings
Volatile Below Avwap Earnings
Tailwinds
Confidence
Celestica Inc. (CLS) is a Toronto-based provider of supply chain and electronics manufacturing services (EMS). The company operates through two primary segments: Connectivity and Cloud Solutions (CCS) and Advanced Technology Solutions (ATS). Its service portfolio spans the entire product lifecycle, including design, precision machining, systems integration, and after-market repair.
The company serves a diverse range of end markets, including aerospace and defense, HealthTech, and industrial sectors. A key driver for the EMS sector is the increasing trend of original equipment manufacturers (OEMs) outsourcing complex assembly and logistics to reduce capital expenditures. Celestica specifically targets high-growth areas through strategic collaborations, such as its partnership with AMD to develop rack-scale AI infrastructure for hyperscale data centers.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data on ValueRay.
As a global entity, Celestica maintains operations across North America and Asia, focusing on hardware platform solutions and open-source software integration. This business model relies on high-volume production and intricate supply chain management to maintain margins in a competitive, capital-intensive industry.
- Hyperscaler demand for AI infrastructure drives Connectivity and Cloud Solutions revenue
- Strategic AMD partnership for Helios platform accelerates high-value AI server growth
- Diversification into aerospace and defense segments stabilizes Advanced Technology Solutions margins
- Global supply chain shifts impact component sourcing costs and manufacturing efficiency
- Capital expenditure cycles of cloud service providers dictate quarterly hardware demand volume
| Net Income: 959.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.16 > 1.0 |
| NWC/Revenue: 9.53% < 20% (prev 13.11%; Δ -3.58% < -1%) |
| CFO/TA 0.11 > 3% & CFO 887.9m > Net Income 959.7m |
| Net Debt (570.9m) to EBITDA (1.32b): 0.43 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.7m) vs 12m ago -1.03% < -2% |
| Gross Margin: 11.61% > 18% (prev 10.67%; Δ 0.93% > 0.5%) |
| Asset Turnover: 196.7% > 50% (prev 172.9%; Δ 23.80% > 0%) |
| Interest Coverage Ratio: 21.51 > 6 (EBIT TTM 1.18b / Interest Expense TTM 55.0m) |
| A: 0.16 (Total Current Assets 6.40b - Total Current Liabilities 5.08b) / Total Assets 8.21b |
| B: 0.06 (Retained Earnings 513.2m / Total Assets 8.21b) |
| C: 0.17 (EBIT TTM 1.18b / Avg Total Assets 7.02b) |
| D: 0.33 (Book Value of Equity 2.05b / Total Liabilities 6.16b) |
| Altman-Z'' = 2.74 = A |
| DSRI: 1.08 (Receivables 3.17b/2.14b, Revenue 13.8b/10.1b) |
| GMI: 0.92 (GM 10.67% / 11.61%) |
| AQI: 0.98 (AQ_t 0.13 / AQ_t-1 0.14) |
| SGI: 1.37 (Revenue 13.8b / 10.1b) |
| TATA: 0.01 (NI 959.7m - CFO 887.9m) / TA 8.21b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of June 21, 2026, the stock is trading at USD 372.55 with a total of 2,079,700 shares traded.
Over the past week, the price has changed by -3.45%,
over one month by +9.85%,
over three months by +31.04% and
over the past year by +175.49%.
Celestica has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy CLS.
- StrongBuy: 6
- Buy: 6
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 444.1 | 19.2% |
P/E Trailing = 47.5932
P/E Forward = 38.7597
P/S = 3.2778
P/B = 21.5414
P/EG = 1.0
Revenue TTM = 13.8b USD
EBIT TTM = 1.18b USD
EBITDA TTM = 1.32b USD
Long Term Debt = 746.5m USD (from longTermDebt, last quarter)
Short Term Debt = 25.9m USD (from shortTermDebt, last quarter)
Debt = 948.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 176.5m
Net Debt = 570.9m USD (calculated: Debt 948.9m - CCE 378.0m)
Enterprise Value = 45.8b USD (45.2b + Debt 948.9m - CCE 378.0m)
Interest Coverage Ratio = 21.51 (Ebit TTM 1.18b / Interest Expense TTM 55.0m)
EV/FCF = 92.89x (Enterprise Value 45.8b / FCF TTM 492.7m)
FCF Yield = 1.08% (FCF TTM 492.7m / Enterprise Value 45.8b)
FCF Margin = 3.57% (FCF TTM 492.7m / Revenue TTM 13.8b)
Net Margin = 6.95% (Net Income TTM 959.7m / Revenue TTM 13.8b)
Gross Margin = 11.61% ((Revenue TTM 13.8b - Cost of Revenue TTM 12.2b) / Revenue TTM)
Gross Margin QoQ = 10.80% (prev 11.52%)
Tobins Q-Ratio = 5.57 (Enterprise Value 45.8b / Total Assets 8.21b)
Interest Expense / Debt = 5.79% (Interest Expense 55.0m / Debt 948.9m)
Taxrate = 14.84% (167.2m / 1.13b)
NOPAT = 1.01b (EBIT 1.18b * (1 - 14.84%))
Current Ratio = 1.26 (Total Current Assets 6.40b / Total Current Liabilities 5.08b)
Debt / Equity = 0.46 (Debt 948.9m / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = 0.43 (Net Debt 570.9m / EBITDA 1.32b)
Debt / FCF = 1.16 (Net Debt 570.9m / FCF TTM 492.7m)
Total Stockholder Equity = 2.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.67% (Net Income 959.7m / Total Assets 8.21b)
RoE = 47.71% (Net Income TTM 959.7m / Total Stockholder Equity 2.01b)
RoCE = 42.85% (EBIT 1.18b / Capital Employed (Equity 2.01b + L.T.Debt 746.5m))
RoIC = 36.24% (NOPAT 1.01b / Invested Capital 2.78b)
WACC = 16.17% (E(45.2b)/V(46.1b) * Re(16.41%) + D(948.9m)/V(46.1b) * Rd(5.79%) * (1-Tc(0.15)))
Discount Rate = 16.41% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -92.01 | Cagr: -1.43%
[DCF] Terminal Value 56.78% ; FCFF base≈408.6m ; Y1≈468.4m ; Y5≈689.4m
[DCF] Fair Price = 32.44 (EV 4.30b - Net Debt 570.9m = Equity 3.73b / Shares 115.0m; r=16.17% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.95 | EPS CAGR: 86.65% | SUE: 0.18 | # QB: 0
Revenue Correlation: 97.96 | Revenue CAGR: 22.56% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.31 | Chg30d=+0.00% | Revisions=+78% | Analysts=17
EPS next Quarter (2026-09-30): EPS=2.69 | Chg30d=+0.00% | Revisions=+78% | Analysts=16
EPS current Year (2026-12-31): EPS=10.29 | Chg30d=+0.00% | Revisions=+81% | GrowthEPS=+70.1% | GrowthRev=+54.9%
EPS next Year (2027-12-31): EPS=14.96 | Chg30d=-0.39% | Revisions=+81% | GrowthEPS=+45.4% | GrowthRev=+40.1%
[Analyst] Revisions Ratio: +81%